TMCnet News

Research and Markets: Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline 2014 - 5 Companies & 9 Drug Profiles
[September 24, 2014]

Research and Markets: Global Paroxysmal Nocturnal Hemoglobinuria Therapeutics Pipeline 2014 - 5 Companies & 9 Drug Profiles


DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/csmwtt/paroxysmal) has announced the addition of the "Paroxysmal Nocturnal Hemoglobinuria - Pipeline Review, H2 2014" report to their offering.

This report provides an overview of the Paroxysmal Nocturnal Hemoglobinuria's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paroxysmal Nocturnal Hemoglobinuria and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain ompetitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.



Scope

  • The report provides a snapshot of the global therapeutic landscape of Paroxysmal Nocturnal Hemoglobinuria
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Paroxysmal Nocturnal Hemoglobinuria and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Paroxysmal Nocturnal Hemoglobinuria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Paroxysmal Nocturnal Hemoglobinuria pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Companies Involved in Therapeutics Development


  • Shire Plc
  • Alnylam Pharmaceuticals, Inc.
  • MABLife S.A.S
  • Omeros Corporation
  • Apellis Pharmaceuticals, Inc.

Drug Profiles

  • Recombinant Coversin
  • APL-2
  • OMS-721
  • Long Acting APL-1
  • Cp-40
  • ALN-CC5
  • Monoclonal Antibody for Paroxysmal Nocturnal Hemoglobinuria
  • MAT-303
  • C1 esterase inhibitor (human)

For more information visit http://www.researchandmarkets.com/research/csmwtt/paroxysmal


[ Back To TMCnet.com's Homepage ]